Cancer
Pfizer signs $3 billion cancer deal
November 18, 2014Research and Development, Sales and Marketing Cancer, Merck KGaA, PD-L1, Pfizer, anti-PD-L1, opdivo
Pfizer has signed a multi-billion dollar deal to develop one of Merck KGaA’s investigational drugs, MSB0010718C, an anti-PD-L1 antibody. The …
Charity ‘deeply concerned’ on CDF changes
November 13, 2014Research and Development, Sales and Marketing CDF, Cancer, NHS, NICE, breakthrough breast cancer, palframan
A leading cancer charity has warned that a number of key drugs are at risk of being withdrawn from patients …
Wales Assembly facing questions over cancer
November 5, 2014Research and Development, Sales and Marketing CDF, Cancer, NHS, Wales, Welsh, assembly, drugs fund, oncology
The state of cancer services in Wales has come under increased scrutiny this week as the country’s ability to provide …
Retrospective study backs Iressa use in oesophageal cancer
November 5, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Cancer Oesophagus Gefitinib, Iressa, gefitinib, oncology
A group of oesophageal cancer patients can increase their survival by six months or more if treated with AstraZeneca’s Iressa, …
BMS lung cancer drug scores in Phase II
October 31, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, NSCLC, bristol myers-squibb, odivo
Bristol-Myers Squibb is still in the hunt to gain significant market share in the PD-1 therapeutic vaccine race after releasing …
More cancer patients surviving for longer
October 31, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, bladder, breast, myeloma, oncology, ons, prostate
Cancer survival rates in England are continuing to improve, though many cancers still have an ‘extremely poor’ prognosis, according to …
Cancer Drugs Fund ‘papering over the cracks of a bigger issue’
October 29, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, Kadcyla, NICE, breast cancer, reform
Breakthrough Breast Cancer has raised concerns to the government this week over the ever-increasing price of new oncology medicines. Over …
Cancer drug discovery system ‘broken’
October 24, 2014Research and Development, Sales and Marketing Cancer, cancer research, oncology, paul workman
The global system for discovering new cancer drugs is ‘broken’ and failing to turn scientific advances into enough innovative new …
Roche and Pharmacyclics agree leukaemia pact
October 17, 2014Research and Development, Sales and Marketing BMS, CLL, Cancer, Gazyva, Pharmacyclics, Roche, imbruvica, leukaemia
Pharmacyclics’s cancer drug Imbruvica will be tested in combination with Roche’s Gazyva in a new partnership announced by the firms. …
New cancer drugs escalate Roche earnings
October 16, 2014Research and Development, Sales and Marketing Cancer, Herceptin (trastuzumab), Kadcyla, Perjeta, Q3, Roche, ado-trastuzumab emtansine, pertuzumab
Roche’s sales saw solid growth in the first nine months of the year, increased by the firm’s new cancer medicines. …
Charity launches second cancer research game
October 9, 2014Medical Communications, Sales and Marketing CRUK, Cancer, amazon, genes in space, oncology, play, reverse the odds
Cancer Research UK has launched its second citizen science game this year called ‘Reverse The Odds’ in an attempt to …
NHS England consults on Cancer Drugs Fund
October 6, 2014Research and Development, Sales and Marketing CDF, Cancer, NHS, NHS England, commissioning, oncology
NHS England is declaring new changes to the way the Cancer Drugs Fund operates in order to plug a major …
BMS therapeutic cancer vaccine given swift FDA appraisal
September 29, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, Vaccine, bristol myers-squibb, keytruda, melanoma, opdivo
Bristol-Myers Squibb has been granted a speedy review for its new cancer immunotherapy drug Opdivo by the FDA for patients …
Roche’s Perjeta sees ‘impressive’ survival rates
September 29, 2014Sales and Marketing Cancer, ESMO, Perjeta, Roche, breast, madrid
Roche’s oncology drug Perjeta combined with other medicines can help certain breast cancer patients live longer. This is according to …
MedImmune and CRUK team up on cancer
September 25, 2014Sales and Marketing AstraZeneca, CRT, CRUK, Cambridge, Cancer, MedImmune
AstraZeneca’s biologics arm MedImmune has joined forces with Cancer Research UK to establish a new research laboratory in Cambridge, UK. …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
